Mechanisms of ErbB receptor negative regulation and relevance in cancer

William H D Fry, Lakmal Kotelawala, Colleen A Sweeney, Kermit L Carraway

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The ErbB family of receptor tyrosine kinases engages a wide variety of signaling pathways that collectively direct transcriptional programs controlling organogenesis during development and tissue maintenance in the adult. These receptors are also frequently found overexpressed or aberrantly activated in various cancers, suggesting that ErbB receptor signaling activity must be very tightly regulated. Sufficient levels of ErbB signaling are necessary to mediate tissue homeostasis, for example, but over-signaling can trigger cellular processes that contribute to cancer initiation or progression. Efforts over the last quarter century have led to a thorough understanding of the signaling pathways that are activated by these receptors and the mechanisms by which ErbB receptors engage these pathways. However, the compensatory negative regulatory mechanisms responsible for attenuating receptor activation have only more recently begun to be explored. Here we review the different known mechanisms of ErbB negative regulation, with particular emphasis on those proteins that exhibit some specificity for the ErbB family. We also describe how loss or suppression of ErbB negative regulators may contribute to tumor development, and discuss how restoration or augmentation of these pathways may represent a novel avenue for the development of ErbB-targeted therapies.

Original languageEnglish (US)
Pages (from-to)697-706
Number of pages10
JournalExperimental Cell Research
Volume315
Issue number4
DOIs
StatePublished - Feb 15 2009

Fingerprint

Neoplasms
Organogenesis
Protein-Tyrosine Kinases
Homeostasis
Maintenance
ErbB Receptors
Proteins
Therapeutics

Keywords

  • ErbB
  • Negative regulator
  • Receptor tyrosine kinase
  • Ubiquitin ligase

ASJC Scopus subject areas

  • Cell Biology

Cite this

Mechanisms of ErbB receptor negative regulation and relevance in cancer. / Fry, William H D; Kotelawala, Lakmal; Sweeney, Colleen A; Carraway, Kermit L.

In: Experimental Cell Research, Vol. 315, No. 4, 15.02.2009, p. 697-706.

Research output: Contribution to journalArticle

@article{d0cabc8f85a54fc4936af3b6cadc4988,
title = "Mechanisms of ErbB receptor negative regulation and relevance in cancer",
abstract = "The ErbB family of receptor tyrosine kinases engages a wide variety of signaling pathways that collectively direct transcriptional programs controlling organogenesis during development and tissue maintenance in the adult. These receptors are also frequently found overexpressed or aberrantly activated in various cancers, suggesting that ErbB receptor signaling activity must be very tightly regulated. Sufficient levels of ErbB signaling are necessary to mediate tissue homeostasis, for example, but over-signaling can trigger cellular processes that contribute to cancer initiation or progression. Efforts over the last quarter century have led to a thorough understanding of the signaling pathways that are activated by these receptors and the mechanisms by which ErbB receptors engage these pathways. However, the compensatory negative regulatory mechanisms responsible for attenuating receptor activation have only more recently begun to be explored. Here we review the different known mechanisms of ErbB negative regulation, with particular emphasis on those proteins that exhibit some specificity for the ErbB family. We also describe how loss or suppression of ErbB negative regulators may contribute to tumor development, and discuss how restoration or augmentation of these pathways may represent a novel avenue for the development of ErbB-targeted therapies.",
keywords = "ErbB, Negative regulator, Receptor tyrosine kinase, Ubiquitin ligase",
author = "Fry, {William H D} and Lakmal Kotelawala and Sweeney, {Colleen A} and Carraway, {Kermit L}",
year = "2009",
month = "2",
day = "15",
doi = "10.1016/j.yexcr.2008.07.022",
language = "English (US)",
volume = "315",
pages = "697--706",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Mechanisms of ErbB receptor negative regulation and relevance in cancer

AU - Fry, William H D

AU - Kotelawala, Lakmal

AU - Sweeney, Colleen A

AU - Carraway, Kermit L

PY - 2009/2/15

Y1 - 2009/2/15

N2 - The ErbB family of receptor tyrosine kinases engages a wide variety of signaling pathways that collectively direct transcriptional programs controlling organogenesis during development and tissue maintenance in the adult. These receptors are also frequently found overexpressed or aberrantly activated in various cancers, suggesting that ErbB receptor signaling activity must be very tightly regulated. Sufficient levels of ErbB signaling are necessary to mediate tissue homeostasis, for example, but over-signaling can trigger cellular processes that contribute to cancer initiation or progression. Efforts over the last quarter century have led to a thorough understanding of the signaling pathways that are activated by these receptors and the mechanisms by which ErbB receptors engage these pathways. However, the compensatory negative regulatory mechanisms responsible for attenuating receptor activation have only more recently begun to be explored. Here we review the different known mechanisms of ErbB negative regulation, with particular emphasis on those proteins that exhibit some specificity for the ErbB family. We also describe how loss or suppression of ErbB negative regulators may contribute to tumor development, and discuss how restoration or augmentation of these pathways may represent a novel avenue for the development of ErbB-targeted therapies.

AB - The ErbB family of receptor tyrosine kinases engages a wide variety of signaling pathways that collectively direct transcriptional programs controlling organogenesis during development and tissue maintenance in the adult. These receptors are also frequently found overexpressed or aberrantly activated in various cancers, suggesting that ErbB receptor signaling activity must be very tightly regulated. Sufficient levels of ErbB signaling are necessary to mediate tissue homeostasis, for example, but over-signaling can trigger cellular processes that contribute to cancer initiation or progression. Efforts over the last quarter century have led to a thorough understanding of the signaling pathways that are activated by these receptors and the mechanisms by which ErbB receptors engage these pathways. However, the compensatory negative regulatory mechanisms responsible for attenuating receptor activation have only more recently begun to be explored. Here we review the different known mechanisms of ErbB negative regulation, with particular emphasis on those proteins that exhibit some specificity for the ErbB family. We also describe how loss or suppression of ErbB negative regulators may contribute to tumor development, and discuss how restoration or augmentation of these pathways may represent a novel avenue for the development of ErbB-targeted therapies.

KW - ErbB

KW - Negative regulator

KW - Receptor tyrosine kinase

KW - Ubiquitin ligase

UR - http://www.scopus.com/inward/record.url?scp=62649175431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62649175431&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2008.07.022

DO - 10.1016/j.yexcr.2008.07.022

M3 - Article

C2 - 18706412

AN - SCOPUS:62649175431

VL - 315

SP - 697

EP - 706

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 4

ER -